Lecap Asset Management Ltd. Makes New Investment in Ralliant Corporation $RAL

Lecap Asset Management Ltd. bought a new position in Ralliant Corporation (NYSE:RAL) during the third quarter, according to its most recent 13F filing with the SEC. The fund bought 19,304 shares of the company’s stock, valued at approximately $844,000.

Other hedge funds have also recently made changes to their positions in the company. Farmers & Merchants Investments Inc. purchased a new position in Ralliant in the second quarter worth about $662,000. GAMMA Investing LLC bought a new stake in shares of Ralliant in the 2nd quarter valued at approximately $56,000. Alpha Omega Wealth Management LLC purchased a new position in shares of Ralliant in the 2nd quarter worth approximately $213,000. Public Employees Retirement System of Ohio bought a new position in shares of Ralliant during the 2nd quarter valued at approximately $1,799,000. Finally, TD Private Client Wealth LLC purchased a new stake in Ralliant during the 2nd quarter valued at $284,000.

Ralliant Price Performance

Shares of RAL opened at $51.28 on Friday. The company has a market cap of $5.78 billion and a price-to-earnings ratio of 40.38. The company has a quick ratio of 1.03, a current ratio of 1.49 and a debt-to-equity ratio of 0.39. Ralliant Corporation has a 1-year low of $40.70 and a 1-year high of $55.08. The firm’s 50-day moving average is $49.15.

Ralliant (NYSE:RAL) last issued its earnings results on Wednesday, November 5th. The company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.02. The company had revenue of $529.10 million for the quarter, compared to analysts’ expectations of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 23rd. Shareholders of record on Monday, December 8th were issued a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date was Monday, December 8th. Ralliant’s dividend payout ratio is currently 15.75%.

Analyst Ratings Changes

Several research analysts have commented on RAL shares. Oppenheimer lifted their price objective on shares of Ralliant from $55.00 to $60.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Truist Financial began coverage on shares of Ralliant in a report on Friday, December 12th. They issued a “buy” rating and a $62.00 target price for the company. Citigroup upgraded shares of Ralliant from a “neutral” rating to a “buy” rating and upped their price target for the company from $53.00 to $61.00 in a report on Monday, December 8th. Barclays increased their price objective on shares of Ralliant from $59.00 to $60.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Ralliant in a research note on Monday, December 29th. Six research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $58.00.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.